CN116554337A - 针对小鼠免疫球蛋白G3亚型（IgG3）兔单克隆抗体及其应用 - Google Patents
针对小鼠免疫球蛋白G3亚型（IgG3）兔单克隆抗体及其应用 Download PDFInfo
- Publication number
- CN116554337A CN116554337A CN202210597752.5A CN202210597752A CN116554337A CN 116554337 A CN116554337 A CN 116554337A CN 202210597752 A CN202210597752 A CN 202210597752A CN 116554337 A CN116554337 A CN 116554337A
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- igg
- subtype
- rabbit monoclonal
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000283973 Oryctolagus cuniculus Species 0.000 title claims abstract description 76
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 18
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 18
- 238000001514 detection method Methods 0.000 claims abstract description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 17
- 238000001262 western blot Methods 0.000 claims abstract description 15
- 238000000684 flow cytometry Methods 0.000 claims abstract description 8
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims abstract description 5
- 230000002163 immunogen Effects 0.000 claims abstract description 4
- 238000005215 recombination Methods 0.000 claims abstract description 4
- 238000012216 screening Methods 0.000 claims abstract description 4
- 238000003384 imaging method Methods 0.000 claims abstract description 3
- 238000003364 immunohistochemistry Methods 0.000 claims abstract description 3
- 238000010369 molecular cloning Methods 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 7
- 230000003053 immunization Effects 0.000 claims description 5
- 238000011587 new zealand white rabbit Methods 0.000 claims description 3
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- 238000004113 cell culture Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 6
- 230000006798 recombination Effects 0.000 abstract description 2
- 238000012258 culturing Methods 0.000 abstract 1
- 238000002965 ELISA Methods 0.000 description 18
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 13
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 241000283707 Capra Species 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000011532 immunohistochemical staining Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 108010089804 glycyl-threonine Proteins 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- OTQSTOXRUBVWAP-NRPADANISA-N Gln-Ser-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O OTQSTOXRUBVWAP-NRPADANISA-N 0.000 description 2
- UWKNTTJNVSYXPC-CIUDSAMLSA-N Lys-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN UWKNTTJNVSYXPC-CIUDSAMLSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- HQTKVSCNCDLXSX-BQBZGAKWSA-N Ser-Arg-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O HQTKVSCNCDLXSX-BQBZGAKWSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- YIGLXQRFQVWFEY-NRPADANISA-N Ala-Gln-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O YIGLXQRFQVWFEY-NRPADANISA-N 0.000 description 1
- NHLAEBFGWPXFGI-WHFBIAKZSA-N Ala-Gly-Asn Chemical compound C[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)N)C(=O)O)N NHLAEBFGWPXFGI-WHFBIAKZSA-N 0.000 description 1
- VHAQSYHSDKERBS-XPUUQOCRSA-N Ala-Val-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O VHAQSYHSDKERBS-XPUUQOCRSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- WVNFNPGXYADPPO-BQBZGAKWSA-N Arg-Gly-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O WVNFNPGXYADPPO-BQBZGAKWSA-N 0.000 description 1
- PRLPSDIHSRITSF-UNQGMJICSA-N Arg-Phe-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PRLPSDIHSRITSF-UNQGMJICSA-N 0.000 description 1
- OWSMKCJUBAPHED-JYJNAYRXSA-N Arg-Pro-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 OWSMKCJUBAPHED-JYJNAYRXSA-N 0.000 description 1
- NUCUBYIUPVYGPP-XIRDDKMYSA-N Asn-Leu-Trp Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O NUCUBYIUPVYGPP-XIRDDKMYSA-N 0.000 description 1
- RDLYUKRPEJERMM-XIRDDKMYSA-N Asn-Trp-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(O)=O RDLYUKRPEJERMM-XIRDDKMYSA-N 0.000 description 1
- KRXIWXCXOARFNT-ZLUOBGJFSA-N Asp-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O KRXIWXCXOARFNT-ZLUOBGJFSA-N 0.000 description 1
- UGKZHCBLMLSANF-CIUDSAMLSA-N Asp-Asn-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O UGKZHCBLMLSANF-CIUDSAMLSA-N 0.000 description 1
- KEBJBKIASQVRJS-WDSKDSINSA-N Cys-Gln-Gly Chemical compound C(CC(=O)N)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CS)N KEBJBKIASQVRJS-WDSKDSINSA-N 0.000 description 1
- HHABWQIFXZPZCK-ACZMJKKPSA-N Cys-Gln-Ser Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CS)N HHABWQIFXZPZCK-ACZMJKKPSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- FJAYYNIXQNERSO-ACZMJKKPSA-N Gln-Cys-Asp Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)O)C(=O)O)N FJAYYNIXQNERSO-ACZMJKKPSA-N 0.000 description 1
- MADFVRSKEIEZHZ-DCAQKATOSA-N Gln-Gln-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N MADFVRSKEIEZHZ-DCAQKATOSA-N 0.000 description 1
- JXFLPKSDLDEOQK-JHEQGTHGSA-N Gln-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O JXFLPKSDLDEOQK-JHEQGTHGSA-N 0.000 description 1
- IQACOVZVOMVILH-FXQIFTODSA-N Glu-Glu-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O IQACOVZVOMVILH-FXQIFTODSA-N 0.000 description 1
- JVZLZVJTIXVIHK-SXNHZJKMSA-N Glu-Trp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)O)N JVZLZVJTIXVIHK-SXNHZJKMSA-N 0.000 description 1
- DWUKOTKSTDWGAE-BQBZGAKWSA-N Gly-Asn-Arg Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DWUKOTKSTDWGAE-BQBZGAKWSA-N 0.000 description 1
- HQRHFUYMGCHHJS-LURJTMIESA-N Gly-Gly-Arg Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N HQRHFUYMGCHHJS-LURJTMIESA-N 0.000 description 1
- GGAPHLIUUTVYMX-QWRGUYRKSA-N Gly-Phe-Ser Chemical compound OC[C@@H](C([O-])=O)NC(=O)[C@@H](NC(=O)C[NH3+])CC1=CC=CC=C1 GGAPHLIUUTVYMX-QWRGUYRKSA-N 0.000 description 1
- NSVOVKWEKGEOQB-LURJTMIESA-N Gly-Pro-Gly Chemical compound NCC(=O)N1CCC[C@H]1C(=O)NCC(O)=O NSVOVKWEKGEOQB-LURJTMIESA-N 0.000 description 1
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 1
- LLWQVJNHMYBLLK-CDMKHQONSA-N Gly-Thr-Phe Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LLWQVJNHMYBLLK-CDMKHQONSA-N 0.000 description 1
- CUVBTVWFVIIDOC-YEPSODPASA-N Gly-Thr-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CN CUVBTVWFVIIDOC-YEPSODPASA-N 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- QADCTXFNLZBZAB-GHCJXIJMSA-N Ile-Asn-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C)C(=O)O)N QADCTXFNLZBZAB-GHCJXIJMSA-N 0.000 description 1
- JZNVOBUNTWNZPW-GHCJXIJMSA-N Ile-Ser-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)O)N JZNVOBUNTWNZPW-GHCJXIJMSA-N 0.000 description 1
- VGSPNSSCMOHRRR-BJDJZHNGSA-N Ile-Ser-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N VGSPNSSCMOHRRR-BJDJZHNGSA-N 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- UGTHTQWIQKEDEH-BQBZGAKWSA-N L-alanyl-L-prolylglycine zwitterion Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UGTHTQWIQKEDEH-BQBZGAKWSA-N 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- NRFGTHFONZYFNY-MGHWNKPDSA-N Leu-Ile-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NRFGTHFONZYFNY-MGHWNKPDSA-N 0.000 description 1
- FKQPWMZLIIATBA-AJNGGQMLSA-N Leu-Lys-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FKQPWMZLIIATBA-AJNGGQMLSA-N 0.000 description 1
- SIGZKCWZEBFNAK-QAETUUGQSA-N Leu-Ser-Ser-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 SIGZKCWZEBFNAK-QAETUUGQSA-N 0.000 description 1
- LCNASHSOFMRYFO-WDCWCFNPSA-N Leu-Thr-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O LCNASHSOFMRYFO-WDCWCFNPSA-N 0.000 description 1
- QWWPYKKLXWOITQ-VOAKCMCISA-N Leu-Thr-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(C)C QWWPYKKLXWOITQ-VOAKCMCISA-N 0.000 description 1
- QESXLSQLQHHTIX-RHYQMDGZSA-N Leu-Val-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QESXLSQLQHHTIX-RHYQMDGZSA-N 0.000 description 1
- GQFDWEDHOQRNLC-QWRGUYRKSA-N Lys-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN GQFDWEDHOQRNLC-QWRGUYRKSA-N 0.000 description 1
- MNGBICITWAPGAS-BPUTZDHNSA-N Met-Ser-Trp Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O MNGBICITWAPGAS-BPUTZDHNSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- WKTSCAXSYITIJJ-PCBIJLKTSA-N Phe-Ile-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O WKTSCAXSYITIJJ-PCBIJLKTSA-N 0.000 description 1
- UNBFGVQVQGXXCK-KKUMJFAQSA-N Phe-Ser-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O UNBFGVQVQGXXCK-KKUMJFAQSA-N 0.000 description 1
- JMVQDLDPDBXAAX-YUMQZZPRSA-N Pro-Gly-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 JMVQDLDPDBXAAX-YUMQZZPRSA-N 0.000 description 1
- AFXCXDQNRXTSBD-FJXKBIBVSA-N Pro-Gly-Thr Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O AFXCXDQNRXTSBD-FJXKBIBVSA-N 0.000 description 1
- PCWLNNZTBJTZRN-AVGNSLFASA-N Pro-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 PCWLNNZTBJTZRN-AVGNSLFASA-N 0.000 description 1
- GOMUXSCOIWIJFP-GUBZILKMSA-N Pro-Ser-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GOMUXSCOIWIJFP-GUBZILKMSA-N 0.000 description 1
- 108010054530 RGDN peptide Proteins 0.000 description 1
- FMDHKPRACUXATF-ACZMJKKPSA-N Ser-Gln-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O FMDHKPRACUXATF-ACZMJKKPSA-N 0.000 description 1
- XXXAXOWMBOKTRN-XPUUQOCRSA-N Ser-Gly-Val Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O XXXAXOWMBOKTRN-XPUUQOCRSA-N 0.000 description 1
- FLONGDPORFIVQW-XGEHTFHBSA-N Ser-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO FLONGDPORFIVQW-XGEHTFHBSA-N 0.000 description 1
- PIQRHJQWEPWFJG-UWJYBYFXSA-N Ser-Tyr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O PIQRHJQWEPWFJG-UWJYBYFXSA-N 0.000 description 1
- JGUWRQWULDWNCM-FXQIFTODSA-N Ser-Val-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O JGUWRQWULDWNCM-FXQIFTODSA-N 0.000 description 1
- CAJFZCICSVBOJK-SHGPDSBTSA-N Thr-Ala-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAJFZCICSVBOJK-SHGPDSBTSA-N 0.000 description 1
- UZJDBCHMIQXLOQ-HEIBUPTGSA-N Thr-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O UZJDBCHMIQXLOQ-HEIBUPTGSA-N 0.000 description 1
- XXNLGZRRSKPSGF-HTUGSXCWSA-N Thr-Gln-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N)O XXNLGZRRSKPSGF-HTUGSXCWSA-N 0.000 description 1
- LGNBRHZANHMZHK-NUMRIWBASA-N Thr-Glu-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)O LGNBRHZANHMZHK-NUMRIWBASA-N 0.000 description 1
- BNGDYRRHRGOPHX-IFFSRLJSSA-N Thr-Glu-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O BNGDYRRHRGOPHX-IFFSRLJSSA-N 0.000 description 1
- PAXANSWUSVPFNK-IUKAMOBKSA-N Thr-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N PAXANSWUSVPFNK-IUKAMOBKSA-N 0.000 description 1
- BVOVIGCHYNFJBZ-JXUBOQSCSA-N Thr-Leu-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O BVOVIGCHYNFJBZ-JXUBOQSCSA-N 0.000 description 1
- VRUFCJZQDACGLH-UVOCVTCTSA-N Thr-Leu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VRUFCJZQDACGLH-UVOCVTCTSA-N 0.000 description 1
- KZSYAEWQMJEGRZ-RHYQMDGZSA-N Thr-Leu-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O KZSYAEWQMJEGRZ-RHYQMDGZSA-N 0.000 description 1
- KERCOYANYUPLHJ-XGEHTFHBSA-N Thr-Pro-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O KERCOYANYUPLHJ-XGEHTFHBSA-N 0.000 description 1
- RVMNUBQWPVOUKH-HEIBUPTGSA-N Thr-Ser-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RVMNUBQWPVOUKH-HEIBUPTGSA-N 0.000 description 1
- CYCGARJWIQWPQM-YJRXYDGGSA-N Thr-Tyr-Ser Chemical compound C[C@@H](O)[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CO)C([O-])=O)CC1=CC=C(O)C=C1 CYCGARJWIQWPQM-YJRXYDGGSA-N 0.000 description 1
- YOPQYBJJNSIQGZ-JNPHEJMOSA-N Thr-Tyr-Tyr Chemical compound C([C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 YOPQYBJJNSIQGZ-JNPHEJMOSA-N 0.000 description 1
- FYBFTPLPAXZBOY-KKHAAJSZSA-N Thr-Val-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O FYBFTPLPAXZBOY-KKHAAJSZSA-N 0.000 description 1
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 1
- HYVLNORXQGKONN-NUTKFTJISA-N Trp-Ala-Lys Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 HYVLNORXQGKONN-NUTKFTJISA-N 0.000 description 1
- LGEYOIQBBIPHQN-UWJYBYFXSA-N Tyr-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 LGEYOIQBBIPHQN-UWJYBYFXSA-N 0.000 description 1
- PZXUIGWOEWWFQM-SRVKXCTJSA-N Tyr-Asn-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O PZXUIGWOEWWFQM-SRVKXCTJSA-N 0.000 description 1
- UPODKYBYUBTWSV-BZSNNMDCSA-N Tyr-Phe-Cys Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CS)C(O)=O)C1=CC=C(O)C=C1 UPODKYBYUBTWSV-BZSNNMDCSA-N 0.000 description 1
- ZPFLBLFITJCBTP-QWRGUYRKSA-N Tyr-Ser-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)NCC(O)=O ZPFLBLFITJCBTP-QWRGUYRKSA-N 0.000 description 1
- JIODCDXKCJRMEH-NHCYSSNCSA-N Val-Arg-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N JIODCDXKCJRMEH-NHCYSSNCSA-N 0.000 description 1
- UGFMVXRXULGLNO-XPUUQOCRSA-N Val-Ser-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O UGFMVXRXULGLNO-XPUUQOCRSA-N 0.000 description 1
- VBTFUDNTMCHPII-FKBYEOEOSA-N Val-Trp-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O VBTFUDNTMCHPII-FKBYEOEOSA-N 0.000 description 1
- VBTFUDNTMCHPII-UHFFFAOYSA-N Val-Trp-Tyr Natural products C=1NC2=CC=CC=C2C=1CC(NC(=O)C(N)C(C)C)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 VBTFUDNTMCHPII-UHFFFAOYSA-N 0.000 description 1
- MIAZWUMFUURQNP-YDHLFZDLSA-N Val-Tyr-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N MIAZWUMFUURQNP-YDHLFZDLSA-N 0.000 description 1
- NLNCNKIVJPEFBC-DLOVCJGASA-N Val-Val-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O NLNCNKIVJPEFBC-DLOVCJGASA-N 0.000 description 1
- 108010081404 acein-2 Proteins 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 1
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 108010069926 arginyl-glycyl-serine Proteins 0.000 description 1
- 108010060035 arginylproline Proteins 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 108010062266 glycyl-glycyl-argininal Proteins 0.000 description 1
- 108010081551 glycylphenylalanine Proteins 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 108010038745 tryptophylglycine Proteins 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明涉及生物技术领域，公开了兔抗小鼠免疫球蛋白G3亚型(IgG3)的特异性单克隆抗体OTIR8B8，所述的抗体是利用分选特异B细胞并培养筛选及分子克隆重组产生。所述兔单克隆抗体OTIR8B8的免疫原为天然小鼠IgG3(mIgG3)抗体，其OTIR8B8抗体轻链(VL)的氨基酸序列如SEQIDNO.1所示；OTIR8B8抗体的重链(VH)的氨基酸序列如SEQIDNo.2所示。所述OTIR8B8抗体的VL包括3个抗原决定簇：CDR1、CDR2和CDR3，其氨基酸序列分别如SEQIDNo.3‑5所示，所述OTIR8B8抗体的VH区域包括3个抗原决定簇：CDR1、CDR2和CDR3，其氨基酸序列分别如SEQIDNo.6‑8所示。本发明还涉及抗小鼠免疫球蛋白G3亚型(IgG3)特异性兔单克隆抗体在免疫检测工具中的应用，包含但不限于用于一抗的化学发光、荧光和显色检测，适合各种应用，例如细胞成像、流式细胞检测、蛋白质免疫印迹及免疫组织化学，也为下一步工程抗体的制备提供基础。
Description
技术领域
本发明属于生物技术领域，尤其涉及抗小鼠免疫球蛋白G3亚型(IgG3)兔单克隆抗体及其在免疫检测方面应用。
背景技术
亲和结合物/抗体是生命科学中最常用的工具之一，用于研究蛋白以及它们在各种生物通路和疾病中的功能。目前在科学研究领域及医药领域抗体种属应用最广泛的包括鼠源抗体、人源抗体、兔源抗体。这些抗体可以特异性识别兴趣靶标，然后通过酶标二抗或荧光素标记二抗显示信号。目前抗鼠IgG及抗人IgG标记抗体市场应用十分之广，可应用于酶联免疫吸附(ELISA)、免疫印迹 (Westernblot)、免疫组织化学染色(IHC)、流式细胞术(FCM)及免疫共沉淀等，最常用的标记方法包括辣根过氧化物酶(HRP)，碱性磷酸酶，生物素，荧光素等。
目前制备抗鼠IgG抗体的主要方法是将IgG免疫球蛋白直接免疫兔或羊或驴等动物产生免疫学清多克隆抗体，然后纯化后应用。但是研发IgG重链和轻链不同类型特异性抗体，多克隆抗体是远远不够的，需要制备单克隆抗体，特别是针对不同亚型mIgG的单克隆抗体。
鼠IgG单克隆抗体重链包括IgG1,IgG2a,IgG2b,IgG2c,IgG3五种亚型，轻链包括κ链及λ链两种类型，κ链：λ链约为20：1。目前市场上大都是多克隆抗体，如山羊多抗、绵羊多抗、驴多抗等，很少有单克隆抗体，特别是没有兔抗mIgG3 特异性单克隆抗体。
在研发抗mIgG3抗体时，因为要获得特异性识别mIgG3，而不与mIgG1, mIgG2a,mIgG2b,mIgG2c,humanIgG1(hIgG1),humanIgG2(hIgG2),humanIgG3(hIgG 3),humanIgG4(hIgG4),RatIgG,Rabbit IgG(RabIgG)有交叉反应的单克隆抗体，我们遇到了很多困难。在此期间我们经过多次分选优化及大量筛选最终获得了本发明申请兔单克隆抗体OTIR8B8。
特异性识别抗mIgG3亚型的抗体，包括裸抗及标记抗体市场应用十分之广，可应用于酶联免疫吸附(ELISA)、免疫印迹(Westernblot)、免疫组织化学染色 (IHC)、流式细胞术(FCM)及免疫共沉淀等。然而以上应用实验的核心为特异性结合mIgG3的单克隆抗体，其性能的优劣直接决定着整个检测的灵敏度和特异性。因此，寻找高特异性和高敏感性的抗mIgG3的抗体是建立检测mIgG3 方法的关键。检索中国、美国、EPO、WIPO等专利网站，利用mIgG3或 mIgG3+monoclonal antibody或antibody作为关键词，有关与mIgG3具有高亲和力和特异性结合的单克隆抗体的专利没有查到，有关检测利用抗mIgG3兔单克隆抗体OTIR8B8制备免疫检测试剂盒也未查到；利用mIgG3或 mIgG3+monoclonal antibody或antibody作为关键词，在pubmed未查到与本发明申报内容相关的类似文献。查询国家药品监督管理网站，还没有与mIgG3相关的检测试剂注册。
发明内容
本发明的目的是提供特异性好、亲和力高的抗mIgG3兔单克隆抗体 OTIR8B8及其在免疫检测工具中的应用，包含但不限于用于一抗的化学发光、荧光和显色检测，适合各种应用，例如细胞成像、流式细胞检测、蛋白质免疫印迹及免疫组织化学，也为下一步工程抗体的制备提供基础。
所述兔单克隆抗体为兔单克隆抗体OTIR8B8。
所述兔单克隆抗体OTIR8B8以天然mIgG3抗体为免疫原，通过免疫注射新西兰大白兔，取免疫兔子外周血单核细胞(PMBCs)，分选特异性B细胞培养、筛选并利用分子克隆重组技术获得。
所述兔单克隆抗体OTIR8B8，其轻链可变区(VL)含108aa，其氨基酸序列如SEQ IDNO.1所示；所述抗体的重链(VH)含109aa，其氨基酸序列如SEQ IDNo.2所示。
所述兔单克隆抗体OTIR8B8，其中VL区域包括3个抗原决定簇：CDR1、 CDR2和CDR3，抗原决定簇的区域相应地分别为27aa-34aa，52aa-54aa和 91aa-98aa。其氨基酸序列分别如SEQ ID No.3-5所示。
所述兔单克隆抗体OTIR8B8，其中VH区域包括3个抗原决定簇：CDR1、 CDR2和CDR3，抗原决定簇的区域相应地分别为25aa-32aa，50aa-56aa和 93aa-98aa。其氨基酸残基序列分别如SEQ ID No.6-8所示。
所述的兔单克隆抗体OTIR8B8可以与mIgG3高特异性结合，可通过本领域技术人员所公知的的方法，做为一抗或各种标记二抗使用。尤其是，做为酶标二抗或荧光素标记二抗应用于免疫组化检测、免疫印迹检测及流式细胞检测。
附图说明
图1为兔单克隆抗体OTIR8B8重链和轻链全长扩增产物的电泳图，M为 DNA分子量Marker；
图2为兔单克隆抗体OTIR8B8特异识别天然mIgG3抗体的Westernblot检测结果图；
图3为兔单克隆抗体OTIR8B8特异识别mIgG3抗体线性ELISA检测结果图；
图4为兔单克隆抗体OTIR8B8与其它种属IgG交叉反应ELISA检测结果图；
图5为辣根过氧化物酶标记兔单克隆抗体OTIR8B8特异识别天然mIgG3 抗体的Westernblot检测结果图；
图6为辣根过氧化物酶标记兔单克隆抗体OTIR8B8特异识别mIgG3抗体的 ELISA检测结果图。
具体实施方式
下面结合具体实施例，进一步阐述本发明。应理解，这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法,通常按照常规条件、实验室手册中所述的条件或按照制造厂商所建议的条件。
实施例1:mIgG3兔单克隆抗体的制备
一、mIgG3免疫原的制备
采购Rockland公司mIgG3抗体做为免疫原
二、动物免疫
上述采购的mIgG3抗体以完全弗氏佐剂乳化，采用皮下注射方法免疫2kg 左右的新西兰大白兔，免疫剂量为500μg/只，间隔两周后进行第二次免疫，以不完全弗氏佐剂乳化，免疫剂量为250μg/只。免疫两次后取尾血以ELISA法梯度稀释测定血清效价；依据ELISA效价128000时的OD450大于1.0为标准，根据结果判定是否收集PBMCs或是继续免疫，选取抗体效价最高的兔子进行PBMCs收集。
三、PBMCs分离、特异性B细胞分选、克隆重组将兔仰卧固定在手术台上，将心脏部位被毛减掉，用酒精消毒皮肤，选择心搏最明显处用50ml注射器穿刺，针头刺入心脏后即有血液涌入注射器，取得所需血量后迅速将针头拔出，将注射器中的全血转入无菌50ml管中，与等量的PBS混匀后逐滴缓慢的加入到淋巴细胞分离液上方，室温400×g离心30分钟，离心后，液面由上至下分为四层：黄色血浆层、白色薄膜层即单个核细胞层、分离液层及红细胞层，小心吸取单个核细胞层并用PBS洗涤去除血小板和淋巴细胞分离液后即可获得兔PBMCs。从兔PBMCs中继续分选抗原特异性的B细胞进行培养，培养后的B 细胞上清用抗原包被的ELISA板筛选阳性克隆。阳性克隆的细胞收集裂解后提取RNA并反转录成cDNA,天然配对的兔单克隆抗体轻重链全长序列从对应阳性克隆的cDNA中被扩增出来，通过克隆重组方法构建兔单克隆抗体表达载体，并经测序确定序列。扩增的全长PCR产物结果如图1。
四、单克隆抗体的制备和纯化为了获得识别人mIgG3蛋白的兔单克隆抗体，本发明将兔单克隆抗体重链、轻链基因装载在表达载体上，将质粒转染HEK293 细胞；转染120-144小时获得培养上清中含有重组的识别人mIgG3蛋白的兔单克隆抗体。收取细胞悬液，离心取上清，亲和层析法进行抗体纯化。以BCA法测定纯化后的单抗浓度，再分装、冻干。
实施例2:抗mIgG3兔单克隆抗体OTIR8B8的鉴定
一、兔单克隆抗体OTIR8B8 Westernblot鉴定
采用Westernblot(WB)检测。mIgG1、mIgG2a、mIgG2b、mIgG3每个亚型各选择2个不同样品，每个蛋白上样100ng进行SDS-PAGE，转膜后进行WB 检测。
结果显示，兔单克隆抗体OTIR8B8能特异识别mIgG3，不识别mIgG1、 mIgG2a、mIgG2b，抗体稀释比：1:5000-10000,1mg/ml，结果见图2。
二、兔单克隆抗体OTIR8B8 ELISA鉴定
mIgG1、mIgG2a、mIgG2b、mIgG3、mIgG3 Fc、mIgG3 F(ab')2抗体包被酶标板，4℃过夜；第二天取出酶标板，PBST洗涤一次，1％BSA溶液37℃封闭2 小时，PBST洗涤3次；每孔加入兔单克隆抗体OTIR8B8100μl，浓度分别为10、 3、1、0.3、0ng/ml，37℃孵育1小时；孵育完成后取出酶标板，PBST洗涤3 次，分别加入HRP标记的羊抗兔二抗作为检测抗体，37℃孵育1小时；孵育完成后取出酶标板，PBST洗涤5次，加入TMB底物，37℃显色10min。取出后加终止液，在酶标仪上测定OD450读数。采用同样方法检测兔单克隆抗体 OTIR8B8与其它种属IgG交叉识别。
结果显示，兔单克隆抗体OTIR8B8能特异识别mIgG3，且识别的是Fc片段，不识别mIgG1、mIgG2a、mIgG2b，效价可达到1.5*107，结果见图3。图4 结果说明兔单克隆抗体OTIR8B8能特异识别mIgG3，不与其它种属IgG交叉识别，包括human IgG(hIgG1、hIgG2、hIgG3、hIgG4),RatIgG,RabIgG。
实施例3:兔单克隆抗体OTIR8B8可变区基因与氨基酸序列分析
以OTIR8B8抗体的重组质粒为DNA模板，根据模板上轻链及重链5'端载体序列设计轻链可变区及重链可变区测序引物，采用测序仪ABI 3730进行测序。经测序获得兔单克隆抗体OTIR8B8轻链及重链可变区的核苷酸序列。
利用互联网，在http://www.imgt.org上使用IMGT/V-QUEST分析软件，分别将轻链与重链的核苷酸序列进行测序结果数据分析，得到兔单克隆抗体 OTIR8B8的轻链氨基酸序列如SEQ ID NO.1所示，重链氨基酸序列如 SEQ ID NO.2所示。VL全长为108个氨基酸，其FR的4个结构域氨基酸数分别为26、17、36和10，CDR的3个结构域氨基酸数分别为8、3和8，CDR1、 CDR2和CDR3的区域相应地分别为27aa-34aa，52aa-54aa和91aa-98aa，其氨基酸序列分别为QSVYNNNW、KAS、QGTYSGGT。
通过分析，所述兔单克隆抗体OTIR8B8 VH全长为109个氨基酸，其FR 的4个结构域氨基酸数分别为24、17、36和11，CDR的3个结构域氨基酸数分别为8、7和6，CDR1、CDR2和CDR3分别为25aa-32aa，50aa-56aa和93aa-98aa，其氨基酸序列分别为GFSLSSYA、INAGNRP、SRGDNL。
实施例4:HRP标记兔单克隆抗体OTIR8B8作为二抗的鉴定
一、HRP标记兔单克隆抗体OTIR8B8：
1、兔单克隆抗体OTIR8B8溶于PH9.6的碳酸氢钠溶液中；
2、取一定质量的HRP溶于去离子水中，加入高碘酸钠反应30min，加入乙二醇继续反应30min，过夜透析；
3、称取一定量的硼氢化钠溶于去离子水中，向交联完毕的抗体-HRP溶液中加入硼氢化钠，反应2h，过夜透析；
4、将获得的HRP标记抗体加入等量的甘油-20摄氏度保存。
二、鉴定：
1.HRP标记兔单克隆抗体OTIR8B8 Westernblot鉴定
采用Western blot(WB)检测。取mIgG3抗体100ng进行SDS-PAGE，转膜后孵育HRP标记的兔单克隆抗体OTIR8B8进行WB检测。
结果显示，HRP标记的兔单克隆抗体OTIR8B8能很好的识别mIgG3 Fc 区域，分子量50KD左右，抗体稀释比：1:5000-10000,1mg/ml，结果见图5。
三、兔单克隆抗体OTIR8B8 ELISA鉴定
羊抗鼠IgG包被酶标板，4℃过夜；第二天取出酶标板，PBST洗涤一次， 1％BSA溶液37℃封闭2小时，PBST洗涤3次；每孔加入mIgG3抗体100ul，浓度为0.2ug/ml，37℃孵育1小时；孵育完成后取出酶标板，PBST洗涤3次，加入HRP标记的OTIR8B8作为检测抗体，1ug/ml开始倍比稀释7个梯度，37℃孵育1小时；孵育完成后取出酶标板，PBST洗涤5次，加入TMB底物，37℃显色10min。取出后加终止液，在酶标仪上测定OD450读数。
结果显示，HRP标记的兔抗mIgG3 OTIR8B8作为二抗能很好的检测 mIgG3抗体信号，1mg/ml时稀释比可以达到36K-18K，优于商品化羊抗鼠IgG 多克隆抗体(作为二抗可同时检测mIgG1、mIgG2a、mIgG2b、mIgG3)，结果见图6。
序列表
<110> 无锡傲锐东源生物科技有限公司
<120> 针对小鼠免疫球蛋白G3亚型（IgG3）兔单克隆抗体及其应用
<160> 8
<170> SIPOSequenceListing 1.0
<210> 1
<211> 108
<212> PRT
<213> Oryctolagus cuniculus
<400> 1
Ala Gln Val Leu Thr Gln Thr Pro Ser Ser Val Ser Ala Ala Val Gly
1 5 10 15
Gly Thr Val Thr Ile Asn Cys Gln Ser Ser Gln Ser Val Tyr Asn Asn
20 25 30
Asn Trp Leu Val Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu
35 40 45
Leu Ile Tyr Lys Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe
50 55 60
Arg Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Val
65 70 75 80
Gln Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Gly Thr Tyr Ser Gly
85 90 95
Gly Thr Phe Gly Gly Gly Thr Glu Val Val Val Glu
100 105
<210> 2
<211> 109
<212> PRT
<213> Oryctolagus cuniculus
<400> 2
Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro
1 5 10 15
Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Ser Tyr Ala
20 25 30
Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly
35 40 45
Phe Ile Asn Ala Gly Asn Arg Pro Tyr Tyr Ala Ser Trp Ala Lys Gly
50 55 60
Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Asp Leu Lys Ile Thr
65 70 75 80
Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ser Arg Gly Asp
85 90 95
Asn Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser
100 105
<210> 3
<211> 8
<212> PRT
<213> Oryctolagus cuniculus
<400> 3
Gln Ser Val Tyr Asn Asn Asn Trp
1 5
<210> 4
<211> 3
<212> PRT
<213> Oryctolagus cuniculus
<400> 4
Lys Ala Ser
1
<210> 5
<211> 8
<212> PRT
<213> Oryctolagus cuniculus
<400> 5
Gln Gly Thr Tyr Ser Gly Gly Thr
1 5
<210> 6
<211> 8
<212> PRT
<213> Oryctolagus cuniculus
<400> 6
Gly Phe Ser Leu Ser Ser Tyr Ala
1 5
<210> 7
<211> 7
<212> PRT
<213> Oryctolagus cuniculus
<400> 7
Ile Asn Ala Gly Asn Arg Pro
1 5
<210> 8
<211> 6
<212> PRT
<213> Oryctolagus cuniculus
<400> 8
Ser Arg Gly Asp Asn Leu
1 5
Claims (7)
1.抗小鼠免疫球蛋白G3亚型(IgG3)的特异性兔单克隆抗体，其特征在于：所述兔单克隆抗体为兔单克隆抗体OTIR8B8。
2.根据权利要求1所述的抗小鼠免疫球蛋白G3亚型(IgG3)特异性兔单克隆抗体OTIR8B8，其特征在于：兔单克隆抗体OTIR8B8以天然mIgG3抗体为免疫原，通过免疫注射新西兰大白兔，取免疫兔子外周血单核细胞(PMBCs)，分选特异性B细胞培养、筛选并利用分子克隆重组技术获得。
3.根据权利要求2所述的抗小鼠免疫球蛋白G3亚型(IgG3)特异性兔单克隆抗体OTIR8B8，其特征在于：特异性识别Fcγ区域。
4.根据权利要求2所述的抗小鼠免疫球蛋白G3亚型(IgG3)特异性兔单克隆抗体OTIR8B8，其特征在于:其轻链可变区(VL)含108aa，其氨基酸序列如SEQ ID NO.1所示；所述抗体的重链(VH)含109aa，其氨基酸序列如SEQ ID No.2所示。
5.根据权利要求2所述的抗小鼠免疫球蛋白G3亚型(IgG3)特异性兔单克隆抗体OTIR8B8，其中VL区域包括3个抗原决定簇：CDR1、CDR2和CDR3，抗原决定簇的区域相应地分别为27aa-34aa，52aa-54aa和91aa-98aa。其氨基酸序列分别如SEQ ID No.3-5所示。
6.根据权利要求2所述的抗小鼠免疫球蛋白G3亚型(IgG3)特异性兔单克隆抗体OTIR8B8，其中VH区域包括3个抗原决定簇：CDR1、CDR2和CDR3，抗原决定簇的区域相应地分别为25aa-32aa，50aa-56aa和93aa-98aa。其氨基酸残基序列分别如SEQ ID No.6-8所示。
7.权利要求2所述的抗小鼠免疫球蛋白G3亚型(IgG3)特异性兔单克隆抗体的应用，其特征在于:能特异性识别小鼠免疫球蛋白G3亚型(IgG3)，不交叉识别小鼠免疫球蛋白G1亚型(IgG1)、小鼠免疫球蛋白G2a亚型(IgG2a)、小鼠免疫球蛋白G2b亚型(IgG2b)；用于小鼠免疫球蛋白G3亚型(IgG3)在免疫检测工具中的应用，包含但不限于用于一抗的化学发光、荧光和显色检测，例如细胞成像、流式细胞检测、蛋白质免疫印迹及免疫组织化学等应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210597752.5A CN116554337A (zh) | 2022-05-31 | 2022-05-31 | 针对小鼠免疫球蛋白G3亚型（IgG3）兔单克隆抗体及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210597752.5A CN116554337A (zh) | 2022-05-31 | 2022-05-31 | 针对小鼠免疫球蛋白G3亚型（IgG3）兔单克隆抗体及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116554337A true CN116554337A (zh) | 2023-08-08 |
Family
ID=87490395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210597752.5A Pending CN116554337A (zh) | 2022-05-31 | 2022-05-31 | 针对小鼠免疫球蛋白G3亚型（IgG3）兔单克隆抗体及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116554337A (zh) |
-
2022
- 2022-05-31 CN CN202210597752.5A patent/CN116554337A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112250763B (zh) | 靶向SARS-CoV-2冠状病毒的抗体及其诊断和检测用途 | |
| PT1881064E (pt) | Anticorpo monoclonal anti-núcleo de hcv | |
| CN105087497A (zh) | 杂交瘤细胞株zjeb8-01、抗埃博拉病毒gp蛋白单克隆抗体及其制备和应用 | |
| CN110616192A (zh) | 一种抗人神经丝轻链（nefl）的单克隆抗体及其应用 | |
| EP2757111A1 (en) | Anti-human norovirus gii antibody | |
| CN113683688B (zh) | 抗人类免疫缺陷病毒ⅰ型p24抗原（hiv-1 p24）兔单克隆抗体及其应用 | |
| CN111004324A (zh) | 一种钙卫蛋白单克隆抗体及其应用 | |
| CN114349855B (zh) | 新型冠状病毒Delta突变株特异性抗体及其应用 | |
| KR100832870B1 (ko) | 사스 코로나바이러스 뉴클레오캡시드 단백질에 대한 단클론항체 및 이것의 용도 | |
| WO1986002364A1 (en) | Monoclonal antibodies and their use | |
| JP6808178B2 (ja) | ヒトパルボウイルスｂ１９抗原および抗体の同時検出方法及びキット | |
| KR102660061B1 (ko) | 항 열대열 말라리아 원충 hrp-ii 항체 | |
| JP2007145775A (ja) | ノロウイルスｇｉの高感度検出方法 | |
| CN114213541B (zh) | 一种全能核酸酶的单克隆抗体及其制备方法 | |
| CN114349852B (zh) | 抗h3n2流感病毒血凝素蛋白单克隆抗体zju32-01及其在检测中的应用 | |
| CN116554337A (zh) | 针对小鼠免疫球蛋白G3亚型（IgG3）兔单克隆抗体及其应用 | |
| CN105842440B (zh) | 人c‑反应蛋白荧光定量检测试纸卡 | |
| KR100832867B1 (ko) | 사스 코로나바이러스 뉴클레오캡시드 단백질에 대한 단클론항체 및 이것의 용도 | |
| CN105949312B (zh) | 抗人pct抗体及其应用 | |
| JPWO2019167874A1 (ja) | Ａｐｏａ４に対するモノクローナル抗体、免疫学的測定方法及び測定用キット | |
| CN116143931B (zh) | 一种抗人IgM抗体及其制备方法和用途 | |
| CN114933652B (zh) | 一种抗念珠菌甘露聚糖单克隆抗体及其应用 | |
| KR101287602B1 (ko) | 신장형 및 호흡기형 감염성 기관지염 바이러스를 인식하는 항체 및 그의 용도 | |
| JPH06153979A (ja) | 魚類イリドウイルスに対するモノクローナル抗体並びに該抗体を製造するためのハイブリドーマ及び方法 | |
| CN111378035B (zh) | 抗恶性疟原虫hrp-ii重组抗体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |